MOONLAKE IMMUNOTHERAPEUTICS (MLTX)
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Decision of the US District Court for the Southern District of New York in the TriZetto re-trial
Décision du tribunal américain du district Sud de New York dans le cadre du nouveau procès TriZetto
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Immediate Report
Mulvihill Canadian Bank Enhanced Yield ETF Announces Year End Results
Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour lamlitelimab dans la dermatite atopique lors dune session de dernière minute
Press Release: AAD: new results from Sanofis amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session